Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:MED26-ZNF99

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: MED26-ZNF99
	FusionPDB ID: 52753
	FusionGDB2.0 ID: 52753
		Hgene	Tgene
	Gene symbol	MED26	ZNF99
	Gene ID	9441	7652
	Gene name	mediator complex subunit 26	zinc finger protein 99
	Synonyms	CRSP7\|CRSP70	C19orf9\|F8281
	Cytomap	19p13.11	19p12
	Type of gene	protein-coding	protein-coding
	Description	mediator of RNA polymerase II transcription subunit 26ARC70CRSP complex subunit 7activator-recruited cofactor 70 kDa componentcofactor required for Sp1 transcriptional activation subunit 7cofactor required for Sp1 transcriptional activation, subunit	zinc finger protein 99zinc finger protein ENSP00000375192
	Modification date	20200313	20200313
	UniProtAcc	O95402 Main function of 5'-partner protein: FUNCTION: Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional pre-initiation complex with RNA polymerase II and the general transcription factors.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000263390,	ENST00000397104, ENST00000596209,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	16 X 4 X 12=768	2 X 1 X 1=2
	# samples	18	2
	** MAII score	log2(18/768*10)=-2.09310940439148 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(2/2*10)=3.32192809488736
Fusion gene context	PubMed: MED26 [Title/Abstract] AND ZNF99 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: MED26 [Title/Abstract] AND ZNF99 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	MED26(16738683)-ZNF99(22952126), # samples:2
Anticipated loss of major functional domain due to fusion event.	MED26-ZNF99 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. MED26-ZNF99 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. MED26-ZNF99 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. MED26-ZNF99 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	MED26	GO:0006357	regulation of transcription by RNA polymerase II	15989967

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr19:16738683/chr19:22952126)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across MED26 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across ZNF99 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000263390	MED26	chr19	16738683	-	ENST00000397104	ZNF99	chr19	22952126	-	3383	335	263	3382	1040
ENST00000263390	MED26	chr19	16738683	-	ENST00000596209	ZNF99	chr19	22952126	-	2927	335	263	2926	888
ENST00000263390	MED26	chr19	16738682	-	ENST00000397104	ZNF99	chr19	22952126	-	3383	335	263	3382	1040
ENST00000263390	MED26	chr19	16738682	-	ENST00000596209	ZNF99	chr19	22952126	-	2927	335	263	2926	888

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000263390	ENST00000397104	MED26	chr19	16738683	-	ZNF99	chr19	22952126	-	0.0057223	0.9942778
ENST00000263390	ENST00000596209	MED26	chr19	16738683	-	ZNF99	chr19	22952126	-	0.003497034	0.996503
ENST00000263390	ENST00000397104	MED26	chr19	16738682	-	ZNF99	chr19	22952126	-	0.0057223	0.9942778
ENST00000263390	ENST00000596209	MED26	chr19	16738682	-	ZNF99	chr19	22952126	-	0.003497034	0.996503

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for MED26-ZNF99

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
MED26	chr19	16738682	ZNF99	chr19	22952126	335	184	KYVKVFHKYSNSNRYKIIHTGKKPYK
MED26	chr19	16738682	ZNF99	chr19	22952126	335	186	VKVFHKYSNSNRYKIRHTKKKTFKCM
MED26	chr19	16738682	ZNF99	chr19	22952126	335	24	RDRLLQAIDPQSNGSLTFWDVTIEFA
MED26	chr19	16738682	ZNF99	chr19	22952126	335	26	RLLQAIDPQSNGSLTFWDVTIEFALE
MED26	chr19	16738682	ZNF99	chr19	22952126	335	98	WNMKRHEMVTKPPVISSHFTQDFWPD
MED26	chr19	16738683	ZNF99	chr19	22952126	335	184	KYVKVFHKYSNSNRYKIIHTGKKPYK
MED26	chr19	16738683	ZNF99	chr19	22952126	335	186	VKVFHKYSNSNRYKIRHTKKKTFKCM
MED26	chr19	16738683	ZNF99	chr19	22952126	335	24	RDRLLQAIDPQSNGSLTFWDVTIEFA
MED26	chr19	16738683	ZNF99	chr19	22952126	335	26	RLLQAIDPQSNGSLTFWDVTIEFALE
MED26	chr19	16738683	ZNF99	chr19	22952126	335	98	WNMKRHEMVTKPPVISSHFTQDFWPD

Top

Potential FusionNeoAntigen Information of MED26-ZNF99 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

MED26-ZNF99_16738682_22952126.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:05	NRYKIRHTK	0.9962	0.742	10	19
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B39:06	NRYKIIHTG	0.9246	0.52	12	21
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:05	NRYKIIHTGK	0.9997	0.6433	12	22
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:05	NRYKIRHTKK	0.9993	0.7298	10	20
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:05	SNRYKIRHTK	0.9664	0.6575	9	19
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:05	NRYKIIHTGKK	0.9999	0.7199	12	23
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-C15:06	YSNSNRYKI	0.9979	0.853	6	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-C03:07	YSNSNRYKI	0.9952	0.9758	6	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:14	NRYKIIHTG	0.9951	0.574	12	21
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:14	NRYKIRHTK	0.9908	0.6302	10	19
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-C03:08	YSNSNRYKI	0.9707	0.7532	6	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B73:01	NRYKIIHTG	0.9514	0.5569	12	21
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:03	NRYKIRHTK	0.795	0.7616	10	19
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-C12:12	YSNSNRYKI	0.7405	0.7958	6	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-C06:03	YSNSNRYKI	0.7125	0.9655	6	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-C12:04	YSNSNRYKI	0.7045	0.9799	6	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B73:01	NRYKIRHTK	0.3623	0.5189	10	19
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-C02:06	YSNSNRYKI	0.1841	0.9477	6	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:14	NRYKIIHTGK	0.9997	0.5192	12	22
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:14	NRYKIRHTKK	0.9991	0.614	10	20
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:03	NRYKIIHTGK	0.9926	0.6757	12	22
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:14	SNRYKIRHTK	0.9399	0.5451	9	19
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:03	SNRYKIRHTK	0.5463	0.6857	9	19
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:14	NRYKIIHTGKK	0.9998	0.626	12	23
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:03	NRYKIIHTGKK	0.9933	0.7412	12	23
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-A30:01	RYKIRHTK	0.9901	0.8053	11	19
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-C15:05	YSNSNRYKI	0.9974	0.8613	6	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-C15:02	YSNSNRYKI	0.997	0.8272	6	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:10	NRYKIRHTK	0.9954	0.6486	10	19
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:08	NRYKIRHTK	0.9951	0.5519	10	19
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-C03:17	YSNSNRYKI	0.973	0.9137	6	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-A30:01	RYKIRHTKK	0.9696	0.8175	11	20
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-A30:01	KYSNSNRYK	0.9448	0.7186	5	14
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-C07:04	YSNSNRYKI	0.887	0.7903	6	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-C16:04	YSNSNRYKI	0.8805	0.9232	6	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-C16:02	YSNSNRYKI	0.8749	0.9853	6	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-C03:06	YSNSNRYKI	0.7784	0.97	6	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-C12:03	YSNSNRYKI	0.6944	0.8837	6	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-C16:01	YSNSNRYKI	0.6765	0.9527	6	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B07:13	YSNSNRYKI	0.0087	0.6157	6	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:10	NRYKIIHTGK	0.9995	0.5711	12	22
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:10	NRYKIRHTKK	0.9987	0.6665	10	20
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-A30:01	RYKIRHTKKK	0.962	0.8183	11	21
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:10	SNRYKIRHTK	0.9337	0.605	9	19
MED26-ZNF99	chr19	16738682	chr19	22952126	335	HLA-B27:10	NRYKIIHTGKK	0.9997	0.6683	12	23

Top

Potential FusionNeoAntigen Information of MED26-ZNF99 in HLA II

MED26-ZNF99_16738682_22952126.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-0443	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-0447	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-0454	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-0802	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-0809	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-0813	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-0813	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-0815	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-0815	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-0821	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-0824	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-0830	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-0830	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-0832	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-0837	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1105	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1108	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1111	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1114	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1119	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1120	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1121	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1127	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1130	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1130	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1130	SNSNRYKIIHTGKKP	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1131	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1145	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1145	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1164	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1164	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1168	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1169	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1172	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1172	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1182	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1186	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1186	SNRYKIRHTKKKTFK	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1302	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1304	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-13100	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1316	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1316	SNRYKIRHTKKKTFK	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1323	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1326	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1326	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1329	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1331	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1331	SNRYKIRHTKKKTFK	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1331	FHKYSNSNRYKIRHT	3	18
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1331	VFHKYSNSNRYKIRH	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1334	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1336	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1339	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1341	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1343	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1343	SNRYKIRHTKKKTFK	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1346	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1354	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1354	SNRYKIRHTKKKTFK	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1354	NRYKIRHTKKKTFKC	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1354	RYKIRHTKKKTFKCM	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1356	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1363	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1367	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1373	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1374	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1376	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1377	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1382	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1385	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1385	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1386	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1386	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1393	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1396	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1397	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1399	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1402	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1402	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1403	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1403	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1407	FHKYSNSNRYKIIHT	5	20
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1407	VFHKYSNSNRYKIIH	4	19
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1407	KVFHKYSNSNRYKII	3	18
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1407	FHKYSNSNRYKIRHT	3	18
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1407	VFHKYSNSNRYKIRH	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1407	KVFHKYSNSNRYKIR	1	16
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1407	HKYSNSNRYKIRHTK	4	19
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1409	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1414	FHKYSNSNRYKIIHT	5	20
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1414	FHKYSNSNRYKIRHT	3	18
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1414	VFHKYSNSNRYKIRH	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1416	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1416	SNRYKIRHTKKKTFK	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1419	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1424	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1424	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1427	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1430	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1436	FHKYSNSNRYKIIHT	5	20
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1436	FHKYSNSNRYKIRHT	3	18
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1436	VFHKYSNSNRYKIRH	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1440	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1440	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1441	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1441	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1442	FHKYSNSNRYKIIHT	5	20
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1442	VFHKYSNSNRYKIIH	4	19
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1442	FHKYSNSNRYKIRHT	3	18
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1442	VFHKYSNSNRYKIRH	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1442	KVFHKYSNSNRYKIR	1	16
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1444	FHKYSNSNRYKIIHT	5	20
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1444	FHKYSNSNRYKIRHT	3	18
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1444	VFHKYSNSNRYKIRH	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1446	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1446	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1446	SNSNRYKIIHTGKKP	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1447	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1451	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1463	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1467	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1467	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1468	FHKYSNSNRYKIIHT	5	20
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1468	VFHKYSNSNRYKIIH	4	19
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1468	FHKYSNSNRYKIRHT	3	18
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1468	VFHKYSNSNRYKIRH	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1477	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1477	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1485	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1489	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1489	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1493	FHKYSNSNRYKIRHT	3	18
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1493	VFHKYSNSNRYKIRH	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1494	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1494	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1498	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1498	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1502	VKVFHKYSNSNRYKI	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1502	YVKVFHKYSNSNRYK	1	16
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1502	VKVFHKYSNSNRYKI	0	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1508	VKVFHKYSNSNRYKI	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1508	YVKVFHKYSNSNRYK	1	16
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1508	VKVFHKYSNSNRYKI	0	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1514	VKVFHKYSNSNRYKI	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1514	YVKVFHKYSNSNRYK	1	16
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1514	VKVFHKYSNSNRYKI	0	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1519	VKVFHKYSNSNRYKI	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1519	YVKVFHKYSNSNRYK	1	16
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1519	VKVFHKYSNSNRYKI	0	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1526	VKVFHKYSNSNRYKI	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1526	YVKVFHKYSNSNRYK	1	16
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1526	VKVFHKYSNSNRYKI	0	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1531	VKVFHKYSNSNRYKI	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1531	YVKVFHKYSNSNRYK	1	16
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1531	VKVFHKYSNSNRYKI	0	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1538	VKVFHKYSNSNRYKI	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1538	YVKVFHKYSNSNRYK	1	16
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1538	VKVFHKYSNSNRYKI	0	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1539	VKVFHKYSNSNRYKI	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1539	YVKVFHKYSNSNRYK	1	16
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1539	VKVFHKYSNSNRYKI	0	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1544	VKVFHKYSNSNRYKI	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1544	YVKVFHKYSNSNRYK	1	16
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1544	VKVFHKYSNSNRYKI	0	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1547	VKVFHKYSNSNRYKI	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1547	YVKVFHKYSNSNRYK	1	16
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB1-1547	VKVFHKYSNSNRYKI	0	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0101	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0101	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0101	SNSNRYKIIHTGKKP	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0102	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0102	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0102	SNSNRYKIIHTGKKP	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0103	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0103	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0103	SNSNRYKIIHTGKKP	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0103	YVKVFHKYSNSNRYK	1	16
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0103	VKVFHKYSNSNRYKI	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0103	VKVFHKYSNSNRYKI	0	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0103	SNRYKIRHTKKKTFK	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0103	NSNRYKIRHTKKKTF	8	23
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0104	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0104	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0104	SNSNRYKIIHTGKKP	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0105	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0105	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0105	SNSNRYKIIHTGKKP	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0108N	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0108N	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0108N	SNSNRYKIIHTGKKP	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0111	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0111	YVKVFHKYSNSNRYK	1	16
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0111	VKVFHKYSNSNRYKI	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0111	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0111	SNSNRYKIIHTGKKP	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0111	KVFHKYSNSNRYKII	3	18
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0111	KYVKVFHKYSNSNRY	0	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0111	VKVFHKYSNSNRYKI	0	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0111	KVFHKYSNSNRYKIR	1	16
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0112	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0112	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0112	SNSNRYKIIHTGKKP	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0113	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0113	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0113	SNSNRYKIIHTGKKP	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0114	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0114	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0114	SNSNRYKIIHTGKKP	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0203	YVKVFHKYSNSNRYK	1	16
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0203	VKVFHKYSNSNRYKI	2	17
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0203	SNRYKIIHTGKKPYK	11	26
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0203	KYVKVFHKYSNSNRY	0	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0203	KVFHKYSNSNRYKII	3	18
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0203	NSNRYKIIHTGKKPY	10	25
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0203	SNSNRYKIIHTGKKP	9	24
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0203	VKVFHKYSNSNRYKI	0	15
MED26-ZNF99	chr19	16738682	chr19	22952126	335	DRB5-0203	KVFHKYSNSNRYKIR	1	16

Top

Fusion breakpoint peptide structures of MED26-ZNF99

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
3392	HKYSNSNRYKIIHT	MED26	ZNF99	chr19	16738682	chr19	22952126	335

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
10814	YSNSNRYKIRHTKK	MED26	ZNF99	chr19	16738682	chr19	22952126	335

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of MED26-ZNF99

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	3392	HKYSNSNRYKIIHT	-7.9962	-8.1096
HLA-B14:02	3BVN	3392	HKYSNSNRYKIIHT	-5.70842	-6.74372
HLA-B52:01	3W39	3392	HKYSNSNRYKIIHT	-6.83737	-6.95077
HLA-B52:01	3W39	3392	HKYSNSNRYKIIHT	-4.4836	-5.5189
HLA-A11:01	4UQ2	3392	HKYSNSNRYKIIHT	-10.0067	-10.1201
HLA-A11:01	4UQ2	3392	HKYSNSNRYKIIHT	-9.03915	-10.0745
HLA-A24:02	5HGA	3392	HKYSNSNRYKIIHT	-6.56204	-6.67544
HLA-A24:02	5HGA	3392	HKYSNSNRYKIIHT	-5.42271	-6.45801
HLA-B44:05	3DX8	3392	HKYSNSNRYKIIHT	-7.85648	-8.89178
HLA-B44:05	3DX8	3392	HKYSNSNRYKIIHT	-5.3978	-5.5112
HLA-A02:01	6TDR	3392	HKYSNSNRYKIIHT	-3.37154	-4.40684
HLA-B14:02	3BVN	10814	YSNSNRYKIRHTKK	-6.00367	-7.03897
HLA-B14:02	3BVN	10814	YSNSNRYKIRHTKK	-5.39279	-5.50619
HLA-B52:01	3W39	10814	YSNSNRYKIRHTKK	-6.37513	-6.48853
HLA-B52:01	3W39	10814	YSNSNRYKIRHTKK	-5.71942	-6.75472
HLA-A11:01	4UQ2	10814	YSNSNRYKIRHTKK	-11.5708	-11.6842
HLA-A11:01	4UQ2	10814	YSNSNRYKIRHTKK	-8.11091	-9.14621
HLA-A24:02	5HGA	10814	YSNSNRYKIRHTKK	-6.75661	-6.87001
HLA-A24:02	5HGA	10814	YSNSNRYKIRHTKK	-5.30147	-6.33677
HLA-B27:05	6PYJ	10814	YSNSNRYKIRHTKK	-4.27108	-5.30638
HLA-B44:05	3DX8	10814	YSNSNRYKIRHTKK	-6.47731	-6.59071
HLA-B44:05	3DX8	10814	YSNSNRYKIRHTKK	-3.23433	-4.26963

Top

Vaccine Design for the FusionNeoAntigens of MED26-ZNF99

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
MED26-ZNF99	chr19	16738682	chr19	22952126	10	19	NRYKIRHTK	CAGAGCAACGGATCGTTGACATTTTGG
MED26-ZNF99	chr19	16738682	chr19	22952126	10	20	NRYKIRHTKK	CAGAGCAACGGATCGTTGACATTTTGGGAT
MED26-ZNF99	chr19	16738682	chr19	22952126	11	19	RYKIRHTK	AGCAACGGATCGTTGACATTTTGG
MED26-ZNF99	chr19	16738682	chr19	22952126	11	20	RYKIRHTKK	AGCAACGGATCGTTGACATTTTGGGAT
MED26-ZNF99	chr19	16738682	chr19	22952126	11	21	RYKIRHTKKK	AGCAACGGATCGTTGACATTTTGGGATGTG
MED26-ZNF99	chr19	16738682	chr19	22952126	12	21	NRYKIIHTG	AACGGATCGTTGACATTTTGGGATGTG
MED26-ZNF99	chr19	16738682	chr19	22952126	12	22	NRYKIIHTGK	AACGGATCGTTGACATTTTGGGATGTGACC
MED26-ZNF99	chr19	16738682	chr19	22952126	12	23	NRYKIIHTGKK	AACGGATCGTTGACATTTTGGGATGTGACCATA
MED26-ZNF99	chr19	16738682	chr19	22952126	5	14	KYSNSNRYK	CAGGCCATCGACCCCCAGAGCAACGGA
MED26-ZNF99	chr19	16738682	chr19	22952126	6	15	YSNSNRYKI	GCCATCGACCCCCAGAGCAACGGATCG
MED26-ZNF99	chr19	16738682	chr19	22952126	9	19	SNRYKIRHTK	CCCCAGAGCAACGGATCGTTGACATTTTGG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
MED26-ZNF99	chr19	16738682	chr19	22952126	0	15	KYVKVFHKYSNSNRY	AGGGACCGGCTGCTGCAGGCCATCGACCCCCAGAGCAACGGATCG
MED26-ZNF99	chr19	16738682	chr19	22952126	0	15	VKVFHKYSNSNRYKI	AGGGACCGGCTGCTGCAGGCCATCGACCCCCAGAGCAACGGATCG
MED26-ZNF99	chr19	16738682	chr19	22952126	1	16	KVFHKYSNSNRYKIR	GACCGGCTGCTGCAGGCCATCGACCCCCAGAGCAACGGATCGTTG
MED26-ZNF99	chr19	16738682	chr19	22952126	1	16	YVKVFHKYSNSNRYK	GACCGGCTGCTGCAGGCCATCGACCCCCAGAGCAACGGATCGTTG
MED26-ZNF99	chr19	16738682	chr19	22952126	10	25	NRYKIRHTKKKTFKC	CAGAGCAACGGATCGTTGACATTTTGGGATGTGACCATAGAATTC
MED26-ZNF99	chr19	16738682	chr19	22952126	10	25	NSNRYKIIHTGKKPY	CAGAGCAACGGATCGTTGACATTTTGGGATGTGACCATAGAATTC
MED26-ZNF99	chr19	16738682	chr19	22952126	11	26	RYKIRHTKKKTFKCM	AGCAACGGATCGTTGACATTTTGGGATGTGACCATAGAATTCGCT
MED26-ZNF99	chr19	16738682	chr19	22952126	11	26	SNRYKIIHTGKKPYK	AGCAACGGATCGTTGACATTTTGGGATGTGACCATAGAATTCGCT
MED26-ZNF99	chr19	16738682	chr19	22952126	2	17	VFHKYSNSNRYKIRH	CGGCTGCTGCAGGCCATCGACCCCCAGAGCAACGGATCGTTGACA
MED26-ZNF99	chr19	16738682	chr19	22952126	2	17	VKVFHKYSNSNRYKI	CGGCTGCTGCAGGCCATCGACCCCCAGAGCAACGGATCGTTGACA
MED26-ZNF99	chr19	16738682	chr19	22952126	3	18	FHKYSNSNRYKIRHT	CTGCTGCAGGCCATCGACCCCCAGAGCAACGGATCGTTGACATTT
MED26-ZNF99	chr19	16738682	chr19	22952126	3	18	KVFHKYSNSNRYKII	CTGCTGCAGGCCATCGACCCCCAGAGCAACGGATCGTTGACATTT
MED26-ZNF99	chr19	16738682	chr19	22952126	4	19	HKYSNSNRYKIRHTK	CTGCAGGCCATCGACCCCCAGAGCAACGGATCGTTGACATTTTGG
MED26-ZNF99	chr19	16738682	chr19	22952126	4	19	VFHKYSNSNRYKIIH	CTGCAGGCCATCGACCCCCAGAGCAACGGATCGTTGACATTTTGG
MED26-ZNF99	chr19	16738682	chr19	22952126	5	20	FHKYSNSNRYKIIHT	CAGGCCATCGACCCCCAGAGCAACGGATCGTTGACATTTTGGGAT
MED26-ZNF99	chr19	16738682	chr19	22952126	8	23	NSNRYKIRHTKKKTF	GACCCCCAGAGCAACGGATCGTTGACATTTTGGGATGTGACCATA
MED26-ZNF99	chr19	16738682	chr19	22952126	9	24	SNRYKIRHTKKKTFK	CCCCAGAGCAACGGATCGTTGACATTTTGGGATGTGACCATAGAA
MED26-ZNF99	chr19	16738682	chr19	22952126	9	24	SNSNRYKIIHTGKKP	CCCCAGAGCAACGGATCGTTGACATTTTGGGATGTGACCATAGAA

Top

Information of the samples that have these potential fusion neoantigens of MED26-ZNF99

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
UCEC	MED26-ZNF99	chr19	16738682	ENST00000263390	chr19	22952126	ENST00000397104	TCGA-B5-A5OE
UCEC	MED26-ZNF99	chr19	16738682	ENST00000263390	chr19	22952126	ENST00000596209	TCGA-B5-A5OE

Top

Potential target of CAR-T therapy development for MED26-ZNF99

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to MED26-ZNF99

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to MED26-ZNF99

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)